Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?

The article contrasts Hims & Hers vs. Teladoc for 2026, citing Hims & Hers FY2025 revenue of ~$2.3B (+59% YoY) and net income of ~$128.4M (net margin ~5.5%), versus Teladoc FY2025 revenue of ~$2.5B (-~1.5% YoY) and a still-negative net loss near $200.3M (net margin ~-7.9%). It flags major risks for Hims & Hers including potential FDA restrictions on compounded GLP-1s/peptides and a possible DOJ/HHS investigation, while noting Teladoc’s client concentration (top five ~19% of revenue) and BetterHelp user declines. Valuation is positioned as Teladoc lower P/S (~0.7x vs Hims & Hers ~3.5x) but Hims & Hers higher forward P/E (78.9x vs Teladoc 59.4x), leading the author to prefer Hims & Hers as the “steady growth engine,” despite regulatory overhang.

Analysis

This is less a stock-picking breakthrough than a regime check: the market is paying for HIMS’ growth durability while assigning TDOC a low-probability turnaround. The near-term risk on HIMS is that regulation changes the mix, not the top line; if GLP-1 economics get disrupted, the multiple can compress faster than earnings because the current valuation embeds a long runway of repeat usage. The JPM facility is helpful for working capital, but it also underscores that pharmacy expansion is balance-sheet intensive and can amplify any margin wobble.

TDOC’s problem is structural commoditization. Partnerships with large distributors and health systems may add volume, but they also lower switching costs and make virtual care a feature rather than a moat; that is exactly where AMZN and GOOG/GOOGL can squeeze pricing over 6-18 months. The cleaner second-order winner may be WMT, which can monetize engagement and steer traffic without carrying the full clinical-tech execution risk.

Contrarian view: consensus may be overconfident that HIMS’ growth automatically outruns regulation, while underestimating how little fundamental upside is left in TDOC unless customer concentration improves and BetterHelp stabilizes. The best way to express the view is relative quality, not a blind directional bet. Falsifiers: HIMS gross margin or subscriber growth decelerating after any FDA/DOJ action; TDOC proving durable net adds from enterprise clients and a multi-quarter improvement in paid-user trends.

Key Decisions for Investors

• Long HIMS / short TDOC as a 3-6 month relative-value pair; thesis works if HIMS preserves margin and TDOC remains a low-growth, low-multiple turnaround. Reduce the pair if HIMS falls more than ~15% on regulatory headlines without a corresponding fundamental revision.
• Do not chase TDOC outright here; wait for evidence of sustained enterprise retention and BetterHelp stabilization before considering a long. Otherwise the stock is a value trap with upside capped by ongoing competitive pressure from AMZN and GOOG/GOOGL.
• Watch HIMS on any FDA/DOJ-related volatility as a potential buy-the-dip only if gross margin and subscriber growth remain intact; if not, treat the move as a thesis break rather than a temporary headline fade.
• Prefer WMT over TDOC as the cleaner indirect beneficiary of virtual-care distribution; WMT captures traffic and ecosystem value without taking the same concentration risk or platform commoditization risk.